Fresenius Kabi is offering Vasopressin injection, which is a generic of Par’s Vasostrict.
Generic Vasostrict is a treatment option for adults with vasodilatory shock. It is available in a 20 units per 1 ml single-dose vial.
[Read more: Fresenius Kabi launches generic Zemuro]
“Fresenius Kabi is pleased to offer Vasopressin for our U.S. customers further demonstrating our continued commitment to providing high-quality, cost-saving treatment options to clinicians and the patients they serve,” said John Ducker, president and CEO of Fresenius Kabi USA.
Fresenius Kabi produces Vasopressin Injection in the United States where the company has invested nearly $1 billion on an advanced manufacturing and distribution network dedicated to serving U.S. hospitals and health systems, the company said.
[Read more: Fresenius Kabi intros generic Tepadina]